Autolus Therapeutics to receive $70m in milestone payments from Blackstone Life Sciences

Autolus Therapeutics, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has announced that Blackstone Life Sciences has committed to making two pre-agreed milestone payments of $35m each to Autolus, totalling $70m. The milestones are expected to be recognised in Autolus’ Q4 2022 cash balance.

Autolus and Blackstone entered into a strategic collaboration and financing agreement in November 2021, whereby funds managed by Blackstone agreed to provide up to $250m in equity and product financing to support Autolus’ advancement of obe-cel, its CD19 CAR T cell investigational therapy product candidate, as well as next generation product candidates of obe-cel in B-cell malignancies.

Read the full story from Autolus.